Key result
ACE gene deletion polymorphism was not associated with IgA nephropathy or its progression, with similar DD genotype frequencies in controls, non-ESRF, and ESRF patients.
Why the study?
The role of ACE gene deletion polymorphism as a risk factor for IgA nephropathy and its progression to end-stage renal failure remains conflicting in previous studies.
Is the ACE gene deletion polymorphism associated with an increased risk of IgA nephropathy or its progression to end-stage renal failure in Asians in Singapore?
Case-Control (n=190)
Is the ACE gene deletion polymorphism associated with an increased risk of IgA nephropathy or its progression to end-stage renal failure in Asians in Singapore?
The ACE gene deletion polymorphism does not appear to be a risk factor for IgA nephropathy or a predictor of its progression to end-stage renal failure in the Singaporean Asian population.
Answers are grounded in this paper and cite their sources.
ACE DD genotype was not linked to IgA nephropathy incidence but may hasten progression; leaves open its prognostic role pending larger studies.
The deletion polymorphism of the angiotensin-converting enzyme (ACE) gene has been considered as a risk factor for IgA nephropathy and for its progression to end-stage renal failure. However, results from various studies are conflicting. We had genotyped the ACE gene in 100 patients with IgA nephropathy, 32 of whom were in end-stage renal failure and in 90 normal adult subjects. All DD cases were subjected to confirmation with a second PCR, performed with the insert-specific forward primer. Similar genotype frequencies were obtained for the 90 normal control subjects (II: 47%, ID: 44%, DD: 9%); for the 68 patients not in end-stage renal failure (ESRF) (II: 47%, ID: 46%, DD: 7%) and for the 32 patients with ESRF (II: 53%, ID: 38%, DD: 9%). The genotype frequencies in all 3 series are in Hardy-Weinberg equilibrium. These results suggest that ACE gene polymorphism is not a risk factor for IgA nephropathy and is not a predictor for its progression. Definitive proof of association between ACE gene polymorphism and progression in IgA nephropathy will require a prospective study, controlled for important risk factors, with adequate patient numbers and facility for confirming DD genotypes.
No takes yet. Share an insight, caveat, or question.
Lau et al. (2002) conducted a case-control in IgA nephropathy (n=190). ACE gene deletion polymorphism vs. Normal adult subjects was evaluated on ACE genotype frequencies. ACE gene deletion polymorphism was not associated with IgA nephropathy or its progression, with similar DD genotype frequencies in controls, non-ESRF, and ESRF patients.
Synapse has enriched 10 related papers. Consider them for comparative context: